Shire ’s lanadelumab and SHP647 meet endpoints in respective trials

Irish pharmaceutical company Shire has reported positive topline results from its Phase III HELP clinical trial of lanadelumab to treat hereditary angioedema (HAE) and from the Phase II TURANDOT trial of SHP647 (PF-00547659) for the treatment of ulce …
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news
More News: Clinical Trials